2022ÄêÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»á(ESMO)Äê»áÓÚ9ÔÂ9ÈÕÖÁ13ÈÕÔÚ·¨¹ú°ÍÀèÒÔ¡°ÏßÉÏ+ÏßÏ¡±ÐÎʽ¾ÙÐС£¡£¡£¡£¡£º²É­ÖÆÒ©×ÔÖ÷Á¢ÒìÒ©¼×»ÇËá°¢ÃÀÌæÄáƬ(ÉÌÆ·Ãû£º°¢ÃÀÀÖ^?)Á½ÆªÏà¹ØÑо¿ÕªÒªÈëÑ¡£¬£¬£¬£¬£¬»®·ÖÔÚÔçÆÚºÍÍíÆڷΰ©ÁìÓò´øÀ´×îпÆѧϣÍû¡£¡£¡£¡£¡£

×÷ΪŷÖÞ×ʢÃûºÍ×î¾ßÓ°ÏìÁ¦µÄÖ×Áöѧ¾Û»á£¬£¬£¬£¬£¬Ã¿½ìESMOÄê»á¶¼ÓÐÁè¼Ý30,000ÃûרҵÈËÊ¿¼ÓÈë£¬£¬£¬£¬£¬ÒѾ­³ÉΪÖ×ÁöÁìÓòÁÙ´²×¨¼ÒºÍÒ½Ò©ÆóÒµ¸ú×ÙÈ«Çò×îÐÂÁÙ´²Ñо¿Ï£Íû¡¢ÁÙ´²Êµ¼ù¼°Ò½ÁÆÊÖÒÕÐÅÏ¢µÄ·çÏò±ê¡£¡£¡£¡£¡£

°¢ÃÀÌæÄáÊǺ²É­ÖÆÒ©×ÔÖ÷Ñз¢µÄÊ×ÆäÖйúÔ­´´Èý´úEGFR-TKI£¬£¬£¬£¬£¬Ò²ÊÇÈ«ÇòÊ×ÆäÖÐλÎÞÏ£ÍûÉúÑÄÆÚ(mPFS)Áè¼Ý1Äê(¶þÏßʹÓÃ)µÄÈý´úEGFR-TKI£¬£¬£¬£¬£¬ÒÀ¸½×¿Ô½µÄÁÆЧºÍÇå¾²ÐÔÓÅÊÆ£¬£¬£¬£¬£¬Ò»ÔÙ»ñµÃ¹ú¼ÊȨÍþÈÏ¿É¡£¡£¡£¡£¡£½üÆÚ£¬£¬£¬£¬£¬°¢ÃÀÌæÄáAENEASÑо¿Ð§¹ûÔÚ¹ú¼ÊÖøÃûÖ×ÁöѧÆÚ¿¯¡¶ÁÙ´²Ö×ÁöѧÔÓÖ¾¡·(Journal of Clinical Oncology£¬£¬£¬£¬£¬JCO£¬£¬£¬£¬£¬IF:44.544)½ÒÏþ£¬£¬£¬£¬£¬×îÐÂÄÔתÒÆÑÇ×éÊý¾ÝÁÁÏàÃÀ¹úÁÙ´²Ö×Áöѧ»á(ASCO)Äê»á£¬£¬£¬£¬£¬21ƪժҪÔÚ2022Äê¹ú¼Ê·Î°©Ñо¿Ð­»á(IASLC)ÌìÏ·ΰ©´ó»á(WCLC)½ÒÏþ¡£¡£¡£¡£¡£

±¾½ìESMOÄê»áÉÏ£¬£¬£¬£¬£¬Á½Æª°¢ÃÀÌæÄáÏà¹ØÑо¿ÕªÒªÈëÑ¡£¬£¬£¬£¬£¬´øÀ´°¢ÃÀÌæÄáÓë°ÂÏ£ÌæÄáÔÚEGFRÍ»±äNSCLCÖÐÁÆЧµÄ¼ä½Ó½ÏÁ¿£¬£¬£¬£¬£¬ÒÔ¼°¸¨ÖúÖÎÁÆNSCLCµÄAPPOINTÑо¿µÄ×îÐÂÏ£Íû¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£º1005P

Indirect treatment comparisons of relative efficacy for aumolertinib VS osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)

°¢ÃÀÌæÄáÓë°ÂÏ£ÌæÄáÔÚEGFRÍ»±äNSCLCÖÐÁÆЧµÄ¼ä½Ó½ÏÁ¿

×÷ÕߣºSanjay Popat, The Royal Marsden Hospital

¼ò½é£ºÕâÊÇÒ»Ïî°¢ÃÀÌæÄáÓë°ÂÏ£ÌæÄá¼äPFS¡¢OS¼°ÖÎÁÆʱ´ú·ºÆðÈκÎˮƽ²»Á¼ÊÂÎñ(AG-TEAE)µÄ궨¼ä½ÓÖÎÁƽÏÁ¿£¨indirect treatment comparison, ITC£©£¬£¬£¬£¬£¬Ê¹ÓÃÁËÁ½ÖÖÆÊÎöÒªÁì£¬£¬£¬£¬£¬Ò»ÖÖΪ»ùÓÚAENEASÑо¿£¨°¢ÃÀÌæÄᣩºÍFLAURAÑо¿£¨°ÂÏ£ÌæÄᣩÒѽÒÏþ»ã×ÜÊý¾ÝµÄBucher·¨ITC£¬£¬£¬£¬£¬ÁíÒ»ÖÖΪ»ùÓÚAENEASÑо¿»¼ÕßˮƽÊý¾ÝºÍFLAURAÑо¿ÒѽÒÏþ»ã×ÜÊý¾ÝµÄÄ£ÄâÖÎÁƽÏÁ¿£¨simulated treatment comparison, STC£©¡£¡£¡£¡£¡£STCÖÐƾ֤AENEASÑо¿ÖÐÈËȺÌØÕ÷ºÍЧ¹ûÖ®¼äµÄ¹Øϵ£¬£¬£¬£¬£¬¶ÔAENEASÑо¿ÖеĻ¼Õß¾ÙÐÐÁ˻عéµ÷½â£¬£¬£¬£¬£¬ÒÔÕ¹ÍûFLAURAÑо¿ÈËȺÖеÄÔ¤ÆÚЧ¹û£¬£¬£¬£¬£¬»Ø¹éÄ£×Óƾ֤ȷ¶¨µÄDZÔÚЧӦÐÞÊÎÒòËغÍÑо¿Öв»Æ½ºâµÄÔ¤ºóÒòËؾÙÐÐÁ˵÷½â¡£¡£¡£¡£¡£¹ØÓÚÖ÷ÒªÑо¿ÖÕµãPFS£¬£¬£¬£¬£¬°¢ÃÀÌæÄá±ÈÕÕ°ÂÏ£ÌæÄáµÄBucher HRΪ1.00£¨95% CI:0.72-1.39£©£¬£¬£¬£¬£¬STC HRΪ0.98£¨95% CI:0.68-1.42£©£¬£¬£¬£¬£¬¾ùÌáÐÑÎÞͳ¼Æѧ²î±ð¡£¡£¡£¡£¡£¹ØÓÚOS£¬£¬£¬£¬£¬Bucher HRÎÞͳ¼Æѧ²î±ð£¨1.02¡¾95% CI: 0.67-1.56¡¿£©£¬£¬£¬£¬£¬µ«STC HRÔòÌáÐÑÓÐÀûÓÚ°¢ÃÀÌæÄáµÄOSÊýÖµ²î±ð£¨0.73¡¾95% CI: 0.44-1.22¡¿£©¡£¡£¡£¡£¡£ÆÊÎöʱ£¬£¬£¬£¬£¬AENEASÑо¿µÄOSÊý¾ÝÉÐδ³ÉÊì¡£¡£¡£¡£¡£¹ØÓÚAG-TEAE£¬£¬£¬£¬£¬Bucher ORΪ0.65£¨95% CI:0.08-5.50£©¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£º948TiP

Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components

°¢ÃÀÌæÄḨÖúÖÎÁÆ¿ÉÇгýµÄ¢ñÆÚº¬ÊµÌåºÍ£¯»ò΢ÈéÍ·ÒòËØEGFRÃô¸ÐÍ»±äµÄ·ÇСϸ°û·Î°©µÄÁÆЧºÍÇå¾²ÐÔ(APPOINTÑо¿)

×÷Õߣºº«±¦»Ý  ÉϺ£ÊÐÐØ¿ÆÒ½Ôº

¼ò½é£º²¡ÀíÑÇÐÍÊÇ×ÔÁ¦ÓÚTNM·ÖÆÚµÄÔ¤ºóÖ¸±ê£¬£¬£¬£¬£¬ÆäÖÐЯ´ø΢ÈéÍ·¼°ÊµÌåÒòËصĻ¼ÕßÔ¤ºó½Ï²î¡£¡£¡£¡£¡£¼ÈÍùÑо¿·¢Ã÷£¬£¬£¬£¬£¬Î¢ÈéÍ·ÒòËصı£´æÓëIÆÚ·ÎÏÙ°©»¼Õ߸ü²îµÄÎÞ¸´±¬·¢ÑÄÆÚ£¨RFS£©ÏÔÖøÏà¹Ø£¬£¬£¬£¬£¬×ÝÈ»ÊÇIAÆÚ»¼Õß£¬£¬£¬£¬£¬Êõºó¸¨Öú»¯ÁÆÈÔ¿É´øÀ´»ñÒæ¡£¡£¡£¡£¡£Èý´úEGFR-TKIÒÑÔÚEGFRÍ»±äNSCLC »¼ÕßÖÐÏÔʾ³öÊõºó¸¨ÖúÖÎÁƵÄDZÁ¦£¬£¬£¬£¬£¬µ«ÉÐÎÞÓÃÓÚ¾ßÓиßΣ¸´·¢ÒòËØ£¨ÈçʵÌåºÍ΢ÈéÍ·ÒòËØ£©µÄIÆÚNSCLC»¼ÕßµÄϵͳÑо¿¡£¡£¡£¡£¡£APPOINTÑо¿ÊÇÒ»ÏîÕýÔÚ¾ÙÐÐÖеĶàÖÐÐÄÑо¿£¬£¬£¬£¬£¬½«Ê×´Î̽ÌÖ°¢ÃÀÌæÄáÔÚEGFRÃô¸ÐÍ»±äIÆÚº¬ÊµÌåºÍ/»ò΢ÈéÍ·ÒòËØ¡Ý10£¥µÄNSCLC¸ùÖÎÐÔÊõºó»¼ÕßÖÐ£¬£¬£¬£¬£¬Êõºó¸¨ÖúÖÎÁƵÄÁÆЧºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£Ñо¿ÄâÕÐļ104Àý»¼Õß£¬£¬£¬£¬£¬ÆäÖÐ52Àý½«½ÓÊÜ°¢ÃÀÌæÄá110mg qd×÷Ϊ¸¨ÖúÖÎÁÆ£¨¸¨ÖúÖÎÁÆÍýÏëʱ¼äΪ3Ä꣩£¬£¬£¬£¬£¬52Àý½«½ÓÊÜÇ×½üËæ·ÃÊӲ졣¡£¡£¡£¡£Ö÷ÒªÑо¿ÖÕµãÊÇ2ÄêDFSÂÊ£¬£¬£¬£¬£¬´ÎÒªÑо¿ÖÕµã°üÀ¨3¡¢4¡¢5ÄêµÄDFSÂÊ£¬£¬£¬£¬£¬5ÄêµÄ×ÜÉúÑÄÂÊ£¬£¬£¬£¬£¬Çå¾²ÐÔºÍÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£Ñо¿Ê±´ú»¹½«¼à²âÑ­»·Ö×ÁöDNA¡£¡£¡£¡£¡£ÏÖÔÚÒÑÈë×é9Àý»¼Õß¡£¡£¡£¡£¡£